Triangles: 40k
Vertices: 22.4k
More model informationA potential target for the development of an anti-viral drug for COVID-19 is the main protease of SARS-CoV-2 (Mpro), which encodes the RNA genome. The Mpro is required for transcription and viral replication through the processing and maturation of replicase polyproteins, therefore inhibiting the effects of the protease can prevent the disease from proliferating. The crystal structure of COVID-19 virus Mpro in complex with the mechanism-based inhibitor N3 shows the binding affinity and the key targets to lock in the inhibitor to the enzyme. The N3 covalent bond with the enzyme demonstrates potential deactivation of the protease, critical in developing anti-vrial drugs and halting the threat of an epidemic.
Comments